Summit Therapeutics, Inc. shared on LinkedIn:
“Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
HARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy
First Phase III Ivonescimab Readout beyond NSCLC Demonstrates Significant OS Benefit.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).”
Other articles about Ivonescimab on OncoDaily.